CYTR News and Press, CytRx Corporation From 12/19/19

LOS ANGELES , Dec. 19, 2019 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company, today highlighted Orphazyme A/S received FDA Breakthrough Therapy Designation for arimoclomol for NPC. Breakthrough Therapy Designation is a program inte...

Small-cap stocks have been weighed down by ongoing uncertainty associated with trade deals and interest rate policy, making it harder than ever to spot potential winners and limit risk. Although small-cap stocks could face headwinds if the economy decelerates, there are specific industries and...

Small-cap stocks have underperformed large-cap stocks, and recent manufacturing and services industry data increases concerns that profits could stagnate. The risk of decelerating economic activity to small-cap stocks shouldn't be ignored, but that doesn't mean there aren't sectors, industries...

The following slide deck was published by CytRx Corporation in conjunction with this Read more ...

CytRx ( OTC:CYTR ): Q2 GAAP EPS of -$0.04. More news on: CytRx Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...

LOS ANGELES , Aug. 9, 2019 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology and rare diseases, today announced financial results for the second quarter ended June 30, 2019 , and provided an overview of rec...

LOS ANGELES , July 30, 2019 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology and rare diseases, today highlighted that following a positive meeting with the U.S. Food and Drug Administration (FDA), arimoclo...

LOS ANGELES , July 22, 2019 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has completed enrollment in its Phase 3 clinical trial evalu...

CytRx Corporation (OTCQB: CYTR) , a biopharmaceutical research and development company with expertise in discovering and developing new therapeutics to treat patients with high unmet needs , according to the company’s website (see here: www.cytrx.com ). In this SNNLive In-Studio...

CytRx Corporation (OTCQB: CYTR) , a biopharmaceutical research and development company with expertise in discovering and developing new therapeutics to treat patients with high unmet needs , according to the company’s website (see here: www.cytrx.com ). In this SNNLive In-Studio...